Phase II Study of 18F-rhPSMA-7.3 PET-mpMRI Imaging to Improve Detection of Prostate Cancer and Guide Targeted Biopsy Using TRUS-MR Fusion

What this Trial Is About

Researchers are evaluating an imaging method called 18F-rhPSMA-7.3 PET-multiparametric MRI PET-mpMRI to better identify tumor tissue in men suspected of having prostate cancer. This phase II trial aims to see if this combined imaging technique improves detection of clinically significant prostate cancer compared to current standard imaging. The study also investigates if abnormal tissue seen on imaging matches tumor tissue removed during a biopsy using transrectal ultrasound-magnetic resonance imaging TRUS-MR fusion. Participants receive an intravenous injection of 18F-rhPSMA-7.3, and 50 minutes later, they undergo PET scanning for 30 minutes alongside standard multiparametric MRI mpMRI. Some patients may also have a TRUS-MR fusion biopsy targeting areas identified by the standard mpMRI. This approach seeks to enhance tumor detection and biopsy accuracy by combining PET with mpMRI. During the study, participants undergo imaging scans including PET and mpMRI, and possibly a targeted biopsy. Researchers assess the imagings ability to distinguish clinically significant prostate cancer from less important findings within three months after the scans. The study includes monitoring of imaging results and biopsy outcomes to evaluate how well the new technique detects meaningful prostate cancer. Participant involvement includes imaging appointments and potential biopsy procedures as part of routine care assessment.

An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique